Genome & Company (KOSDAQ: 314130)

Market Cap	107.00B
Revenue (ttm)	23.92B
Net Income (ttm)	-37.88B
Shares Out	30.57M
EPS (ttm)	-1,319.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	334,046
Open	3,670.00
Previous Close	3,700.00
Day's Range	3,545.00 - 3,765.00
52-Week Range	3,275.00 - 8,625.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2024

About Genome & Company

Genome & Company, a clinical stage biotechnology company, researches and develops novel-targeted immuno-oncology therapeutics in the field of immuno-oncology, skin diseases, and autism in South Korea. Its lead product candidate is GEN-001, an oral microbiome therapeutic candidate developed to have immune modulating activities. The company also develops GEN-501 targeting the non-responders of Dupilumab drugs with atopic skin diseases; and GENA-104 for the treatment of solid tumors, as well as microbiome-based products, including therapeutics, co...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2015
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 314130

Financial Performance

In 2023, Genome & Company's revenue was 14.30 billion, an increase of 1.50% compared to the previous year's 14.08 billion. Losses were -47.47 billion, -8.43% less than in 2022.